Goldline Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 13.50 Cr
as on 16-11-2024
- Paid Up Capital ₹ 8.71 Cr
as on 16-11-2024
- Company Age 20 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 8.19 Cr
as on 16-11-2024
- Satisfied Charges ₹ 3.45 Cr
as on 16-11-2024
- Revenue -12.20%
(FY 2023)
- Profit 14.35%
(FY 2023)
- Ebitda 32.71%
(FY 2023)
- Net Worth 2.31%
(FY 2023)
- Total Assets 7.13%
(FY 2023)
About Goldline Pharmaceutical
The Corporate was formerly known as Goldline Pharmaceutical Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 13.50 Cr and a paid-up capital of Rs 8.71 Cr.
The company currently has active open charges totaling ₹8.19 Cr. The company has closed loans amounting to ₹3.45 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Goldline Pharmaceutical Limited India are Ruchi Modi as COMPANY SECRETARY and Swapan Khandelwal as Cfo. Amol Mujumdar, Prashant Rahate, Swapan Khandelwal, and Five other members serve as directors at the Company.
- CIN/LLPIN
U51397MH2004PLC147806
- Company No.
147806
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
02 Aug 2004
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Nagpur, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Goldline Pharmaceutical Limited offer?
Goldline Pharmaceutical Limited offers a wide range of products and services, including Antibiotic Tablets & Capsules, Azithromycin Tablets, Aceclofenac Tablet, Aceclofenac Paracetamol Tablet.
Who are the key members and board of directors at Goldline Pharmaceutical?
Executive Team (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Amol Mujumdar  | Managing Director | 02-Aug-2004 | Current |
| Ruchi Modi | Company Secretary | 05-Nov-2024 | Current |
| Swapan Khandelwal | CFO | 13-Nov-2024 | Current |
Board Members (7)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Prashant Rahate | Director | 05-Nov-2024 | Current |
| Avinash Ambulkar | Director | 16-Jul-2013 | Current |
| Swapan Khandelwal | Whole-Time Director | 11-Apr-2011 | Current |
| Prashant Karkare | Director | 16-Jul-2013 | Current |
| Mehul Ranade | Director | 05-Nov-2024 | Current |
| Renuka Borole | Director | 05-Nov-2024 | Current |
Financial Performance of Goldline Pharmaceutical.
Goldline Pharmaceutical Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 12.2% decrease. The company also saw a substantial improvement in profitability, with a 14.35% increase in profit. The company's net worth moved up by a moderate rise of 2.31%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Goldline Pharmaceutical?
In 2023, Goldline Pharmaceutical had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Breeze - Well Infracon Private LimitedActive 10 years 11 monthsAmol Mujumdar and Swapan Khandelwal are mutual person
- Cherry Voyaging Private LimitedActive 11 years 2 months
Amol Mujumdar and Swapan Khandelwal are mutual person
- Nachiket Natural Resources Private LimitedActive 5 years 7 months
Prashant Rahate and Avinash Ambulkar are mutual person
- Innovmed Institute Of Medical Science Private LimitedActive 4 years 11 months
Prashant Rahate is a mutual person
- Nagpur Institute Of Surgical Sciences & Research Centre Private LimitedActive 11 years 2 months
Prashant Rahate is a mutual person
Charges (Loans)
₹8.19 Cr
₹3.45 Cr
Charges Breakdown by Lending Institutions
- Bank Of India : 8.19 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 02 May 2022 | Bank Of India | ₹4.60 M | Open |
| 27 Dec 2013 | Bank Of India | ₹0.80 M | Open |
| 16 Jan 2013 | Bank Of India | ₹7.65 Cr | Open |
| 17 Feb 2011 | State Bank Of India | ₹3.45 Cr | Satisfied |
How Many Employees Work at Goldline Pharmaceutical?
Goldline Pharmaceutical has a workforce of 85 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Goldline Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Goldline Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
